Hepatocellular Carcinoma Stage I, Radiofrequency Ablation
Conditions
Brief summary
To evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.
Detailed description
Liver cancer is the fourth leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) accounts for 70% to 85% of primary HCC and is the leading cause of death in patients with cirrhosis. We developed a novel no-touch combined directional perfusion radiofrequency ablation system.By inserting two or more electrodes around the tumor and activating them simultaneously.The hypertonic saline solution can be directed into the focal tissue from a lateral pore through a tube within the electrode to provide more uniform and thorough necrosis.The maximum ablation volume was increased while the loss of normal tissue in the non-injection direction was reduced, thus reducing the incidence of postoperative complications. Therefore, the purpose of this study was to evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.
Interventions
None listed
Sponsors
Southwest Hospital, China
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
* Primary hepatocellular carcinoma with a background of cirrhosis * Single shot with diameter ≤ 3cm * The tumor did not invade portal vein, hepatic vein trunk and secondary branches * Child Pugh A/B * ICG-R15 ≤ 30% * 18-70 years old * The follow-up time reached 2 years
Exclusion criteria
* The follow-up time is less than 2 years * multiple lesions or diameter \> 3cm * Previous history of upper gastrointestinal bleeding or severe hypersplenism * Patients with extrahepatic or lymph node metastasis * Wish to receive liver transplantation and hepatectomy * The lesion is adjacent to the gallbladder, important blood vessels and bile ducts in the hilum of the liver and important organs around * severe bleeding tendency, platelet count \< 50 × 10\^9/L, or prothrombin time prolonged \> 3s * Other anti-tumor therapies were accepted before surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of local tumor progression (LTP) | two-years local tumor progression-free survival | LTP was defined as the appearance of new tumor foci near 2 cm at the ablative margin after the local eradication of all tumor cells with RFA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor-free survival | two-years tumor-free survival | The tumor did not recur after treatment. |
Countries
China
Contacts
Primary ContactKai Feng, M.D
Outcome results
None listed